These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 41730)

  • 1. Dopamine agonist-induced hyperglycemia in rats: effects of lergotrile mesylate.
    Schmidt MJ
    Eur J Pharmacol; 1979 Oct; 59(1-2):95-101. PubMed ID: 41730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist-induced hyperglycemia in rats: structure-activity relationships and mechanisms of action.
    Schmidt MJ; Root MA; Hall JL
    Eur J Pharmacol; 1983 Jun; 90(2-3):169-77. PubMed ID: 6135620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dopamine neurons: effect of lergotrile on unit activity and transmitter synthesis.
    Walters JR; Lakoski JM; Baring MD; Eng N
    Eur J Pharmacol; 1979 Dec; 60(2-3):199-210. PubMed ID: 43259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine analog-induced hyperglycemia in rats: involvement of the adrenal medulla and the endocrine pancreas.
    Arnerić SP; Chow SA; Long JP; Fischer LJ
    J Pharmacol Exp Ther; 1984 Mar; 228(3):551-9. PubMed ID: 6142939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of prolactin secretion by lergotrile mesylate: mechanism of action.
    Clemens JA; Smalstig EB; Shaar CJ
    Acta Endocrinol (Copenh); 1975 Jun; 79(2):230-7. PubMed ID: 166535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interactions of bromocriptine and lergotrile with dopamine and alpha-adrenergic receptors.
    Lew JY; Hata F; Ohashi T; Goldstein M
    J Neural Transm; 1977; 41(2-3):109-21. PubMed ID: 21229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction in blood pressure in normal and spontaneously hypertensive rats by lergotrile mesylate.
    Sved AF; Fernstrom JD
    J Pharm Pharmacol; 1979 Dec; 31(12):814-7. PubMed ID: 43364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presynaptic dopamine receptor stimulation in the cardiovascular actions of lergotrile.
    Barrett RJ; Lokhandwala MF
    J Pharmacol Exp Ther; 1981 Jun; 217(3):660-5. PubMed ID: 6112262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stereotyped responses of rats to two 2-halogenoergolines: 2-bromo-alpha-ergocryptine and lergotrile.
    Bergmann F
    Isr J Med Sci; 1982 Jan; 18(1):177-82. PubMed ID: 6121772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discriminative stimulus properties of lergotrile.
    Cunningham KA; Callahan PM; Appel JB
    J Pharmacol Exp Ther; 1984 Jul; 230(1):47-52. PubMed ID: 6146709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lergotrile on 3,4-dihydroxyphenylacetic acid (DOPAC) concentration and dopamine turnover in rat brain.
    Fuller RW; Perry KW
    J Neural Transm; 1978; 42(1):23-35. PubMed ID: 641542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of dopamine and serotonin in the discriminative stimulus effects of lisuride.
    White FJ; Appel JB
    J Pharmacol Exp Ther; 1982 May; 221(2):421-7. PubMed ID: 7077537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential behavioral and biochemical effects of four dopaminergic agonists.
    Gianutsos G; Moore KE
    Psychopharmacology (Berl); 1980; 68(2):139-46. PubMed ID: 6107946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lergotrile mesylate: an in vivo dopamine agonist which blocks dopamine receptors in vitro.
    Kebabian JW; Calne DB; Kebabian PR
    Commun Psychopharmacol; 1977; 1(4):311-8. PubMed ID: 615694
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of insulin release from rat pancreatic islets by drugs that are analogues of dopamine.
    Arnerić SP; Chow SA; Long JP; Fischer LJ
    Diabetes; 1984 Sep; 33(9):888-93. PubMed ID: 6147289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of lergotrile mesylate and methysergide on morphine induced increase in prolactin release.
    Ratner A; Woo W; Yelvington D; Torres K
    Proc West Pharmacol Soc; 1981; 24():335-9. PubMed ID: 6114495
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of the dopamine agonist, lergotrile mesylate, on circulating anterior pituitary hormones in man.
    Thorner MO; Ryan SM; Wass JA; Jones A; Bouloux P; Williams S; Besser GM
    J Clin Endocrinol Metab; 1978 Aug; 47(2):372-8. PubMed ID: 45463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential enhancement of locomotor activity by dopamine agonists following chronic neuroleptic treatment: an animal model of tardive dyskinesia.
    Tye NC; Horsman L; Wright FC; Pullar IA
    Eur J Pharmacol; 1979 Apr; 55(1):103-7. PubMed ID: 35357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence for a peripheral dopaminergic mechanism in the antihypertensive action of lergotrile.
    Sved AF; Fernstrom JD
    Life Sci; 1980 Jul; 27(4):349-54. PubMed ID: 6106139
    [No Abstract]   [Full Text] [Related]  

  • 20. Studies on the antiparkinsonism efficacy of lergotrile.
    Lieberman A; Miyamoto T; Battista AF; Goldstein M
    Neurology; 1975 May; 25(5):459-62. PubMed ID: 166332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.